The results from a long-awaited AstraZeneca trial that tested a combination treatment in lung cancer patients are “crushing,” as one Wall Street analyst put it. The stock is down roughly 15 percent today and the outcome is raising doubts about the ability of the drug maker to forge an independent path.
The MYSTIC trial, as it is known, found that a pair of immunotherapies proved no more effective than chemotherapy at halting tumor growth in newly diagnosed non-small cell lung cancer patients. The company will continue following patients in the study in hopes the combination will help them live longer than chemotherapy alone. The overall survival results are expected in the first half of next year, but this appears to be a reduced opportunity.